Newsfeeds - Spark Newswire

1 minute read

FDA
News

Bristol-Myers Squibb Highlights Abecma Data; Says Reduced Risk Of Disease Progression Or Death By 51% Vs Standard Regimens In Earlier Lines Of Therapy

Today, 9:57 AM

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3

BMY

1 minute read

Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly

By Vandana Singh

Today, 9:57 AM

Bristol-Myers Squibb & Co (NYSE:BMY) has returned the exclusive rights to Dragonfly Therapeutics‘ IL-12 oncology candidate. In 2020, BMS handed out $475 million in…

BMY

2 minute read

Bristol-Myers Squibb Unusual Options Activity For February 01

By Benzinga Insights

Today, 9:57 AM

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

BMY

1 minute read

Prothena Touts Encouraging Data From Early-Stage Alzheimer’s Candidate

By Vandana Singh

Today, 9:57 AM

Prothena Corporation plc (NASDAQ:PRTA) announced topline data from the Phase 1 single ascending dose (SAD) study for PRX005 for Alzheimer’s disease. …

BMY

1 minute read

Pre-Market Outlook

Benzinga Pro’s Top 5 Stocks To Watch For Wednesday, February 1, 2023: QCOM, SPOT, BMY, PTON, VS

By Benzinga Newsdesk

Today, 9:57 AM

QUALCOMM (QCOM) - Will report quarterly results on Thursday after market close. Analysts expect earnings of $2.27 per share on sales of about $9.5 billion. Spotify (SPOT) -

BMY

5 minute read

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch

By Shanthi Rexaline

Today, 9:57 AM

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

AAPL

2 minute read

Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer’s Race To Compete Biogen

By Vandana Singh

Today, 9:57 AM

Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II (NYSE:ROSS), a special-purpose acquisition company founded by former…

BIIB

22 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023

By Benzinga Insights

Today, 9:57 AM

Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…

2 minute read

Looking At Bristol-Myers Squibb’s Recent Unusual Options Activity

By Benzinga Insights

Today, 9:57 AM

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

BMY

2 minute read

Congressman Sells Stocks At End Of 2022 And Retires From Office: Taking Profits Or Warning Sign?

By Chris Katje

Today, 9:57 AM

A member of Congress sold out of his positions of several stocks at the end of 2022. The move came as he finished his term serving the state of Texas and announced his retirement.

BMY